IPO Proteostasis down 20% from debut price that was cut 38% from planned price range

• IPO Proteostasis Therapeutics (NASDAQ:PTI) is getting some rude treatment in its first day of trading. Shares are down 25% from the discounted price of $8 on turnover of 1.4M. The debut price was cut 38% from the (midpoint) of original expected range of $12 - 14.
• Previously: Proteostasis prices IPO well below range at $8; trading commences today (Feb. 11)